Start here if you're new
what it is
Acumen is a biotech company trying to make one Alzheimer’s antibody work.
how it gets paid
Acumen is effectively pre‑product revenue; the balance sheet and periodic filings fund R&D while ACU193 advances in Phase 2 (ALTITUDE‑AD).
what just happened
The latest quarter lost $1.59 a share, and revenue was still blank.
At a glance
C+ balance sheet — struggling to keep the lights on
$(1.71) FY2024 diluted EPS
pre‑revenue · clinical‑stage
1.4 beta
~$198M market cap
xvary composite: 23/100 — weak
What they do
Acumen is a biotech company trying to make one Alzheimer’s antibody work.
Acumen has 61 employees and one lead asset. soluble amyloid-beta oligomers -> toxic protein clumps -> that is the target ACU193 is chasing. You are not buying a portfolio here. You are buying one shot on goal.
How they make money
~$0
product revenue · R&D‑stage
ACU193 (sabirnetug) · Phase 2
pipeline
value driver
The products that matter
Alzheimer's antibody candidate
ACU193 (sabirnetug)
Phase 2 · ALTITUDE‑AD
This is Acumen’s lead clinical program (soluble amyloid‑β oligomers). The ~$198M market cap is a bet on Phase 2 readouts and financing runway—not near‑term product sales.
the whole story
Key numbers
-$1.71
fy2024 eps est
$0
product revenue
n/a
trailing p/e
n/a
dividend yield
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $27M (12% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ABOS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest quarter lost $1.59 a share, and revenue was still blank.
EDGAR showed EPS of -$1.59. Yahoo Finance still shows $0M trailing revenue. That is not a sales story. That is a funding story.
$0M
revenue
-$1.59
eps
n/a
n/a
eps loss
The $1.59 loss per share matters because the company still has no sales.
source: EDGAR and Yahoo Finance, latest quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is Phase 2 failure for ACU193 (sabirnetug) in early Alzheimer’s disease.
med
ACU193 is the whole equity story
There is no diversified revenue base here. ACU193 is the lead clinical program, and the company is worth about $198M. If Phase 2 disappoints, investors are left with a thin balance sheet and no product sales.
Because one asset drives 100% of the thesis, one failed readout would directly pressure most of the current market value.
med
Cash burn can turn into dilution fast
FY2024 EPS is estimated at -$1.71. That's your cleanest shorthand for a business still consuming cash. Add $27M of long-term debt and a C+ balance sheet, and new capital is a live issue.
If cash needs arrive before meaningful trial progress, existing shareholders could get diluted while the business remains pre‑revenue.
med
There is very little outside validation on this page
Institutional ownership data is sparse, analyst target data is missing, and recent insider trades were sales, not purchases. That does not kill the thesis. It does mean you are not getting much external confirmation.
In a volatile small-cap biotech with 5/100 price stability, thin validation can make the stock gap harder on both good news and bad.
ABOS is a one‑asset, pre‑product biotech with about $198M of market value and deep FY2024 losses—the risk picture is concentrated by design.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
Phase 2 ACU193 data
This is the main event. The company has one asset doing all the work, so the readout matters more than any quarterly headline.
cash burn
Whether losses keep tracking near the current profile
FY2024 EPS is estimated at -$1.71 and Q4 EPS is forecast at -$0.45. That is the number path you watch for financing pressure.
balance sheet
Any capital raise before key data
A company with a C+ balance sheet, $27M of long-term debt, and little revenue does not have endless flexibility.
sentiment
Whether outside conviction actually improves
Sparse institutional data, missing target data, and small insider sales leave the story thin on confirmation. If that changes, the stock can rerate quickly.
Analyst rankings
coverage
thin
There is not much published ranking or target support on this page. In human-speak: the street is not doing much of your work for you here.
risk
high
Risk rank 5 and price stability 5/100 translate to the same message: you should expect volatility, not smooth compounding.
source: institutional data
Institutional activity
institutional ownership data for ABOS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive